Egesta lopci biography template
•
Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer
Editorial
Egesta Lopci1, Sabrina Rossi2
Comment on:Toyokawa G, Takada K, Okamoto T, et al. Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer. Anticancer Res 2017;37:1393-401.
Submitted May 15, 2017. Accepted for publication Jun 01, 2017.
doi: 10.21037/tcr.2017.06.42
EZH2 in non-small cell lung cancer (NSCLC)
Epigenetic parameters—as DNA methylation and histone acetylation - play pivotal roles in carcinogenesis (1). Polycomb group (PcG) proteins are epigenetic effectors that maintain the silenced state of genes. The enhancer of zeste homolog 2 (EZH2) is one of the most important components of the polycomb repressive complex 2 (PRC2) and plays an important role in tumorigenesis and cancer progression (2). EZH2 has also been shown to be a key regulator of tumor angiogenesis (3). Overexpression of EZH2 has been associate
•
Evaluating response to immunotherapy with 18F-FDG PET/CT: where do we stand?
In this issue of the EJNMMI, Seban et al. [1] föreslå a prognostic score combining baseline total metabolic tumor volume (TMTV) and the Derived Neutrophil-to-Lymphocyte Ratio (dLNR) to predict overall survival (OS) in non-small fängelse lung cancer (NSCLC) patients receiving immune-checkpoint inhibitors (ICI). In their series of 80 patients, a TMTV >75 and a dLNR >3, previously validated as a biomarker of immune activation bygd other groups [2], resulted as independent predictive factors for shorter OS and worse clinical benefit, the later one established according to RECIST 1.1 criteria and combining objective response (partial or complete) at any time during the course of ICI or stable disease after 6 months of treatment. The same group from Gustave Roussy Institute, had shown in melanoma patients that baseline 18F-FDG husdjur parameters could be used to build a prognostic metabolic score using not o
•
Egesta Lopci, MD, PhD
demo : Research Link Australia
Researcher
Related Links
Publications
Publication
Evaluating response to immunotherapy with 18F-FDG PET/CT: where do we stand?
Publisher: Springer Science and Business Media LLC
Date: 30-01-2020
DOI: 10.1007/S00259-020-04702-4
Publication
IRF4 instructs effector Treg differentiation and immune suppression in human cancer
Publisher: American Society for Clinical Investigation
Date: 11-05-2020
DOI: 10.1172/JCI130426
Publication
Emerging and Evolving Concepts in Cancer Immunotherapy Imaging
Publisher: Radiological Society of North America (RSNA)
Date: 2023
DOI: 10.1148/RADIOL.210518
Publication
Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 04-2017
DOI: 10.1097/MNM.0000000000000656
Publication